Background and Purpose: Metastatic pancreatic neuroendocrine tumors (PNET) are generally not curable; however, some patients may have prolonged survival. New developments demonstrating improved clinical outcomes in these patients treated with temozolomide (TMZ) resulted in its off-label use in National Comprehensive Cancer Network guidelines. However, serious hematologic adverse events (AEs) like agranulocytosis, lymphopenia, and aplastic anemia are not uncommon. At the University of Kansas Cancer Center (KUCC), 3 patients with history of TMZ-treated metastatic PNET developed hematologic malignancies. The purpose of this study is to determine the incidence of secondary malignancies (SM) in this patient population.
Introduction
Metastatic pancreatic neuroendocrine tumors (PNET) are generally not curable; however, some patients may have prolonged survival.
Until recently, metastatic PNET were primarily managed with somatostatin-analogs. New developments demonstrating therapeutic value of temozolomide (TMZ) in these patients resulted in its off-label use in National Comprehensive Cancer Network guidelines. Given alone, or in combination with other therapies, TMZ is associated with improved clinical outcomes. However, serious hematologic adverse events there were 3 patients who developed hematologic malignancies after treatment with TMZ for metastatic PNET. Secondary malignancy in patients with TMZ-treated metastatic PNET have not been well-studied. To determine how common secondary malignancies (SM) are in this patient population, our group conducted a systematic review of the literature.
Objective of the Study
The objective of this study is to determine the prevalence of SM in patients treated with TMZ for PNET.
Methods
A systematic review of all known clinical trials, case reports, and other relevant literature regarding PNET and TMZ published before September 2017 was conducted using PubMed, Cochrane Library and the FDA Adverse Event Reporting System (FAERS).
Results
We analyzed 38 publications (Table 1) 
Discussion
In our study, there were no published reports of SM in TMZ-treated PNET, yet, SM and MDS in TMZ-treated brain tumors are welldocumented. Various studies have shown cytogenetics with therapy-related MDS or leukemia (t-MDS/t-AML) in SM in TMZ-treated brain tumors [1] [2] [3] [4] [5] . In this study, 3 TMZ-treated PNET patients were found to have MDS. Cytogenetics available in 1 patient showed abnormalities in chromosome 7, commonly seen in t-MDS/t-AML.
At KUCC, we report 3 patients who developed leukemia or lymphoma after TMZ for PNET ( Table 2 ). In 1 patient, cytogenetics showed translocation abnormalities in chromosomes 1 and 7, also consistent with t-AML. Figure 1 shows liver biopsy and bone marrow of this patient. All 3 patients at KUCC had metastatic PNET and died due to their hematologic malignancies. TMZ may increase the risk of SM in patients treated for PNET. The leukemogenic potential of TMZ may be underreported. TMZ dosing in PNET is more extensive compared to other malignancies. With increasing use of TMZ in the treatment of PNET, it is anticipated that cases of SM will soon emerge in the literature. Although we observed 3 cases at KUCC, this retrospective review did not find any cases of SM in TMZ-treated metastatic PNET. We believe that the leukemogenic potential of TMZ is underreported. It is important for treatment guidelines to address this risk in the decision to pursue TMZ treatment. We call for consideration of updating treatment guidelines for TMZ in PNET, specifically, indications for initiation of treatment, patient selection, duration of treatment, and surveillance for long-term adverse events, especially for those patients anticipated to have indolent disease and long survival from their PNET. Investigations designed to personalize treatment based on molecular biology may address some of these questions.
